Duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication

Abstract EN

ackground: Metabolic syndrome is a leading cause of morbidity and mortality in patients with schizophrenia.

The prevalence rate is double that of a non-psychiatric population.

Objective: The present study aimed to determine the duration of treatment as a risk factor for metabolic syndrome in patients with schizophrenia receiving antipsychotic medication.

Methods: Structured psychiatric interview was conducted using ICD-10 criteria, laboratory investigation (TG (triglycerides), HDL (high-density lipid), blood pressure, fasting blood glucose and metabolic syndrome based on the national cholesterol education program adult treatment panel three criteria.

Results: The present study showed that 52.9% did not fulfill the criteria for metabolic syndrome with 47.1% meeting the criteria.

The incidence of metabolic syndrome in those who received second-generation antipsychotics was 68.6% while metabolic syndrome in those who received first generation antipsychotics was 25.7%.

Conclusion: There was a statistically significant difference between the incidence of metabolic syndrome and duration of treatment in the two groups being studied.